HPH in the Authentic Athens Marathon

Hellenic Pulmonary Hypertension (HPH) participated in the original Classic Athens Marathon that took place on November 8th, 2015, along with a record of 43,000 runners from all over the world! In that historic international sport event, HPH was represented...

Gilead Announces Encouraging Results For Combined Letairis/Tadalafil Therapy For PAH

By Patricia Silva, PhD Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter,...

PAH Clinical Trial Designs Are Evolving, Paving the Way Toward Improved Therapies

By Maureen Newman  The recent announcement of positive results for the AMBITION trial testing combinatorial ambrisentan and tadalafil in patients with pulmonary arterial hypertension (PAH) is bringing more attention to the need to actively recruit participants for clinical trials. Without patients and clinicians interested in...

Study Highlights Effects of Shortness of Breath, Fatigue in PAH Patients’ Quality of Life

By Patricia Inacio, PhD In a new study entitled “Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension,” researchers determined which symptoms experienced by those with pulmonary arterial hypertension are the most self-limiting and interfering with patients daily quality of...

Volunteer for PH!

HPH seeks people from the health sector, all types of specialist doctors, nurses and caregivers, as well as anybody willing to become a volunteer for PH. Please send us your CV to become a member of our community! E-mail...